Effectiveness of Tolvaptan Treatment in Hyponatremic Patients

Authors : Emel ISIKTAS SAYILAR, Alparslan ERSOY, Yavuz AYAR, Mehmet Fethullah AYDIN, Mahmut YAVUZ

Pages : 43-47

Doi:10.46310/tjim.706226

View : 74 | Download : 12

Publication Date : 2020-04-29

Article Type : Research Paper

Abstract :Objective: Non-peptide vasopressin receptor antagonists insert ignore into journalissuearticles values(vaptans); are effective at increasing sodium in euvolemic and hypervolemic states and appear safe. We aimed to evaluate the efficacy of tolvaptan in euvolemic or hypervolemic hyponatremic patients. Methods: The study included 9 hyponatremic insert ignore into journalissuearticles values(serum sodium level <125 mmol/L); patients. Serum potassium levels of all patients were normal and there was no acid-base disturbance. Patients with hypovolemic status and hepatic dysfunction were excluded from the study. Clinical and laboratory data of patients were obtained before and after tolvaptan insert ignore into journalissuearticles values(7.5 mg/day); treatment. Results: The median age of patients insert ignore into journalissuearticles values(6 females, 3 males); was 66.3 years insert ignore into journalissuearticles values(range, 56-82);. The mean sodium levels before tolvaptan treatment were 120.5 mEq/L insert ignore into journalissuearticles values(SD 2.2, range, 116-124);. The mean sodium levels increased significantly to 132.6±4.0 mEq/L insert ignore into journalissuearticles values(range, 125-140); after tolvaptan treatment at 2.7±1.3 days insert ignore into journalissuearticles values(range, 2-6); insert ignore into journalissuearticles values(p<0.001);. Hyponatremia did not recur after tolvaptan treatment. We did not observe serious adverse event related with tolvaptan treatment. Conclusion: Hyponatremia was a common problem, and tolvaptan can treat hyponatremia effectively and safely in patients with euvolemic or hypervolemic hyponatremia.
Keywords : Arginine vasopressin, heart failure, hyponatremia, syndrome of inappropriate antidiuretic hormone secretion, tolvaptan

ORIGINAL ARTICLE URL